# ABACAVIR; DOLUTEGRAVIR; LAMIVUDINE
> **ANDA216223** · Abbreviated New Drug Application (Generic) · Sponsor: LAURUS LABS LTD · Approved 2022-08-11
## Drug
- **FDA Application Number:** ANDA216223
- **Application type:** Abbreviated New Drug Application (Generic)
- **Brand name:** ABACAVIR; DOLUTEGRAVIR; LAMIVUDINE
- **Generic name:** Abacavir
- **Active ingredients:** ABACAVIR; DOLUTEGRAVIR; LAMIVUDINE
- **Dosage form:** TABLET
- **Route:** ORAL
- **Marketing status:** None (Tentative Approval)
- **Sponsor:** LAURUS LABS LTD
- **First approval:** 2022-08-11
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216223)
---
*MORVS · CC0 1.0*